Introduction {#s1}
============

Breast cancer is one of the most common malignancies in women. According to an estimation from the WHO, more than 508,000 women worldwide died from breast cancer in 2011 ([@B1]). In China, breast cancer is the fourth most common cancer, with an estimated 150,000 cancer cases in 2012 ([@B2]). Early detection and diagnosis of breast cancer has been shown to reduce mortality ([@B3]). Currently, mammography is considered the gold standard in breast cancer early detection, which was also proven to be the only screening method to reduce mortality ([@B4]). However, mammography may fail to identify patients due to the overlapping dense fibroglandular tissue which reduce the visibility of tumor tissue or even entirely conceal the malignant lesions ([@B5]). It was reported that 15--30% of breast cancer was not detected while using full-field digital mammography ([@B6]). In addition, mammography may lead to over-diagnosis and radiation-induced disease. Therefore, in consideration of the limitation of mammography, it is necessary to develop a new non-invasive method to distinguish breast cancer patients from healthy individuals.

Cells can release DNA into the bloodstream, which is described as circulating cell-free DNA (cfDNA) ([@B7]). The cell-free DNA released from tumor cells, in particular, is called circulating tumor DNA (ctDNA) ([@B7]). Although cfDNA is also present in healthy individuals, it is significantly increased in cancer subjects ([@B8]). cfDNA is recognized as a novel biomarker in the diagnosis of cancer, such as gastric cancer ([@B9]), non-small lung cancer ([@B10]), and hepatocellular carcinoma ([@B11]). There are several detection strategies for breast cancer by cfDNA, such as the concentration of cfDNA, cfDNA integrity, microsatellite alteration, gene mutations, DNA methylation, and so on ([@B12]). The concentration of cfDNA is recognized as a quantitative way to detect cfDNA amounts and the initial detection strategy of breast cancer by cfDNA ([@B12]). So far, a number of studies have evaluated the diagnostic value of the concentration of cfDNA for breast cancer, but the results are inconsistent. For instance, Agostini et al. ([@B13]) reported a high sensitivity of 94.8% and a high specificity of 100%, while a study by Tang et al. ([@B14]) showed a low sensitivity of 65.0% and a low specificity of 70.0%. Hence, we conducted this meta-analysis to evaluate the first diagnostic value of the concentration of cfDNA for breast cancer.

Materials and Methods {#s2}
=====================

Search Strategy
---------------

The following databases were searched to identify all potentially relevant studies published before June 2018: PubMed, Cochrane Library, and Web of Science. The retrieving query formulation used for the search were ("cell free DNA" OR "circulating DNA"OR "plasma DNA" OR "serum DNA") AND ("breast cancer" OR "breast carcinoma" OR "breast tumor"). Article language was limited to English. All the reference lists of the identified articles and relevant reviews were also manually screened.

Inclusion and Exclusion Criteria
--------------------------------

The inclusion criteria of eligible studies were as follows: (1) studies about the first diagnosis not the recurrent diagnosis of the concentration of cfDNA for breast cancer; (2) studies with sufficient data for describing or calculating the sensitivity and specificity values; and (3) studies that were case-control studies, prospective, and retrospective cohort studies. The exclusion criteria included: (1) studies that were reviews, case-only studies, conference letters, or editorials and (2) studies with duplicate data reported.

Data Extraction and Quality Assessment
--------------------------------------

Two reviewers (Dandan Yu and Yan Tong) screened titles, abstracts, and full texts independently according to the above criteria. The following data were extracted from enrolled studies in structured forms: first author\'s name, publication year, country, sample size, study type, source of cfDNA, time of sample collection, test method, reference gene, cut-off value, sensitivity, and specificity. Subsequently, two reviewers independently evaluated the quality of selected studies according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) ([@B15]).

Statistical Analysis
--------------------

The pooled statistics with 95% confidence intervals (95% CIs) of sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated. The summary receiver operating characteristic (SROC) curve and the area under curve (AUC) were used to summarize overall diagnostic performance. Additionally, we used the χ^2^ test and inconsistency index (*I*^2^) to quantify the statistical heterogeneity between studies. A *P* \< 0.1 by χ^2^ test and *I*^2^ statistic \>50% indicated substantial heterogeneity ([@B16]). A fixed-effects model was used to calculate the pooled statistics if there was no statistical heterogeneity; otherwise, a random-effects model was conducted. Furthermore, subgroup analysis and meta-regression analysis were carried out to detect the source of heterogeneity. Publication bias was evaluated with Deeks\' funnel plot asymmetry test ([@B17]). *P* \< 0.05 indicated potential publication bias.

All statistical analysis was performed with STATA (version 14.0; Stata Corp, College Station, TX). A *P* \< 0.05 was considered statistically significant, and all *P*-values were two-sided.

Results {#s3}
=======

Study Characteristics and Quality Assessment
--------------------------------------------

The flowchart of literature search and selection were shown in [Figure 1](#F1){ref-type="fig"}. A total of 1,025 records were initially identified by our search strategy. Ultimately, 13 studies ([@B13], [@B14], [@B18]--[@B28]) were eligible for this meta-analysis according to the inclusion criteria and the exclusion criteria. A total of 1,807 subjects including 1,087 breast cancer patients and 720 healthy controls were recruited for analysis. The sensitivity and specificity of cfDNA for breast cancer detection in selected studies ranged from 37.5 to 100% and from 57.1 to 100%, respectively. Characteristics of these studies are summarized in [Table 1](#T1){ref-type="table"}.

![Flow diagram of the study selection process.](fonc-09-00095-g0001){#F1}

###### 

Characteristics of studies included in this meta-analysis of concentration of circulating cell-free DNA in the diagnosis of breast cancer.

  **References**                      **Country**   **No. of P/C**   **Study type**   **Sample**   **Time of sample collection**   **Test method**               **Reference gene**   **Cut of value**               **Sensitivity (%)**   **Specificity (%)**
  ----------------------------------- ------------- ---------------- ---------------- ------------ ------------------------------- ----------------------------- -------------------- ------------------------------ --------------------- ---------------------
  Leon et al. ([@B22])                USA           32/55            Case-control     Serum        BS                              Radioimmu-noassay             --                   50 ng/ml                       37.5                  92.7
  Gal et al. ([@B24])                 UK            96/24            Case-control     Serum        BS                              RT-qPCR                       β-globin             --                             70.8                  93.7
  Huang et al. ([@B18])               China         61/27            Cohort           Plasma       BS                              RT-qPCR                       β-globin             19 ng/ml                       95.1                  88.9
  Catarino et al. ([@B25])            Portugal      175/80           Cohort           Plasma       AS                              RT-qPCR                       hTERT                106.0 ng/mL                    43.4                  91.2
  Kohler et al. ([@B19])              Switzerland   52/70            Cohort           Plasma       BS                              RT-qPCR                       GAPDH                1866 GE/ml                     81.0                  69.0
  Agostini et al. ([@B13])            Italy         39/49            Case-control     Plasma       BS                              RT-qPCR                       ALU115               9.3394 ng/ml                   94.8                  100.0
  Hashad et al. ([@B20])              Egypt         42/27            Case-control     Plasma       BS                              RT-qPCR                       hTERT                34 ng/ml                       97.6                  96.3
  Gong et al. ([@B21])                China         200/100          Cohort           Serum        BS                              RT-qPCR                       GAPDH                471 ng/ml                      94.0                  95.0
  Stötzer et al. ([@B26])             Germany       112/28           Case-control     Plasma       BS                              RT-qPCR                       ALU115               --                             95.0                  57.1
  Agassi et al. ([@B23])              Israel        38/16            Cohort           Serum        BS                              Fluorescent SYBR Gold stain   --                   600 ng/mL                      72.0                  75.0
  Tangvarasittichai et al. ([@B27])   Thailand      100/100          Case-control     Plasma       BS                              Qubit^TM^flu-orometer         --                   120 ng/ml                      100.0                 88.6
  Zhang et al. ([@B28])               China         100/104          Case-control     Serum        BS                              RT-qPCR                       HOTAIR               Relative concent-ration 0.30   80.0                  68.3
  Tang et al. ([@B14])                China         40/40            Case-control     Serum        --                              Fluorescence qPCR             ALU115               300.96 ng/mL                   65.0                  70.0

*P, patients; C, controls; BS, before surgery; AS, after surgery; RT-qPCR, real-time quantitative PCR*.

The quality of selected studies by QUADAS-2 is shown in [Table 2](#T2){ref-type="table"}. To some extent, most studies had a moderate-high quality, the overall quality of these included studies were generally robust.

###### 

Assessment of the methodological quality by QUADAS-2.

  **References**                      **Risk of bias**               **Applicability concerns**                                                                                                                                 
  ----------------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------------
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Diagnostic Value of Concentration of cfDNA for Breast Cancer
------------------------------------------------------------

The pooled sensitivity and specificity of concentration of cfDNA for breast cancer were 87% (95% CI, 73--94%) and 87% (95% CI, 79--93%), respectively ([Figure 2](#F2){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). The pooled DOR was 32.93 (95% CI, 13.52--80.19) ([Figure 3](#F3){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). The SROC curve revealed an AUC of 0.93 (95% CI, 0.91--0.95) ([Figure 4](#F4){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

![Forest plots of sensitivity and specificity for diagnostic value of concentration of circulating cell-free DNA for breast cancer.](fonc-09-00095-g0002){#F2}

###### 

Summary of main results of diagnostic value of concentration of cfDNA for breast cancer.

  **Study group**                              ***N***   **Sensitivity (95% CI)**   ***I*^2^ (%)**   **Specificity (95% CI)**   ***I*^2^ (%)**   **DOR (95% CI)**       ***I*^2^ (%)**   **AUC (95% CI)**
  --------------------------- ---------------- --------- -------------------------- ---------------- -------------------------- ---------------- ---------------------- ---------------- ------------------
  All                                          13        87% (73%−94%)              96.49            87% (79%−93%)              89.91            32.93(13.52--80.19)    85.8             0.93(0.91--0.95)
  Sample of cfDNA             plasma           7         94% (80%−98%)              98.52            89% (75%−96%)              94.26            79.11(19.13--327.12)   85.0             0.97(0.95--0.98)
                              serum            6         74% (56%−86%)              92.54            85% (73%−92%)              85.77            15.80 (4.51--55.34)    88.3             0.87(0.84--0.90)
  Time of sample collection   before surgery   11        90% (78%−96%)              94.1             88% (78%−94%)              89.17            50.15(17.49--143.79)   86.1             0.95(0.93--0.96)
  Test method                 RT--qPCR         9         88% (77%−95%)              97.52            89% (77%−95%)              93.66            46.29(15.82--135.45)   86.8             0.95(0.93--0.96)
                              Not RT--qPCR     4         85% (29%−99%)              95.04            84% (73%−91%)              74.64            16.60 (2.62--105.31)   85.0             0.88(0.85--0.91)

*N, number of studies*.

![Diagnostic odds ratio of sensitivity and specificity for diagnostic value of concentration of circulating cell-free DNA for breast cancer.](fonc-09-00095-g0003){#F3}

![Summary receiver operating characteristic of sensitivity and specificity for diagnostic value of concentration of circulating cell-free DNA for breast cancer.](fonc-09-00095-g0004){#F4}

Sample of cfDNA, the time of sample collection, and test method were taken into consideration for subgroup analysis. With consideration of the sample of cfDNA, studies with cfDNA isolated from plasma revealed that the pooled sensitivity and specificity were 94% (95% CI, 80--98%) and 89% (95% CI, 75--96%), respectively ([Table 3](#T3){ref-type="table"}). The pooled DOR was 79.11 (95% CI, 19.13--327.12), and the SROC curve revealed an AUC of 0.97 (95%CI, 0.95--0.98) ([Table 3](#T3){ref-type="table"}). Studies with cfDNA isolated from serum revealed that the pooled sensitivity and specificity were 74% (95% CI, 56--86%) and 85% (95% CI, 73--92%), respectively ([Table 3](#T3){ref-type="table"}). The pooled DOR was 15.80 (95% CI, 4.51--55.34), and the SROC curve revealed an AUC of 0.87 (95%CI, 0.84--0.90) ([Table 3](#T3){ref-type="table"}).

With consideration of the time of sample collection, studies with samples collected before surgery revealed that the pooled sensitivity and specificity were 90% (95% CI, 78--96%) and 88% (95% CI, 78--94%), respectively ([Table 3](#T3){ref-type="table"}). The pooled DOR was 50.15 (95% CI, 17.49--143.79), and the SROC curve revealed an AUC of 0.95 (95% CI, 0.93--0.96) ([Table 3](#T3){ref-type="table"}).

With consideration of the test method, studies with the test method of real-time qPCR revealed that the pooled sensitivity and specificity were 88% (95% CI, 77--95%) and 89% (95% CI, 77--95%), respectively ([Table 3](#T3){ref-type="table"}). The pooled DOR was 46.29 (95% CI, 15.82--135.45), and the SROC curve revealed an AUC of 0.95 (95% CI, 0.93--0.96) ([Table 3](#T3){ref-type="table"}). Studies without the test method of real-time qPCR showed that the pooled sensitivity and specificity were 85% (95% CI, 29--99%) and 84% (95% CI, 73--91%), respectively ([Table 3](#T3){ref-type="table"}). The pooled DOR was 16.60 (95% CI, 2.62--105.31), and the SROC curve revealed an AUC of 0.88 (95% CI, 0.85--0.91) ([Table 3](#T3){ref-type="table"}).

Meta-Regression Analysis and Publication Bias
---------------------------------------------

To reveal the sources of heterogeneity, we conducted a meta-regression analysis. Covariates including "publication year (recent 5 years)," "region (Asian)," "sample (plasma)," "time of sample collection (before surgery)," and "method (real-time quantitative PCR)" were assessed. We used these covariates to assess their effects on the RDOR. None of them showed any definite influence on heterogeneity and the details of the calculation were showed in [Table 4](#T4){ref-type="table"}. Deeks\' funnel plot asymmetry test was used to assess publication bias. The *P*-value was 0.65, which showed there was no significant evidence of publication bias ([Figure 5](#F5){ref-type="fig"}).

###### 

Meta-regression of effects of study characteristics on diagnostic accuracy of concentration of cfDNA.

  **Covariates**              **Coefficient**   **SE**   ***P***   **RDOR (95% CI)**
  --------------------------- ----------------- -------- --------- ------------------------
  Year                        1.526             6.252    0.299     4.598 (0.184--114.463)
  Region                      −1.862            0.207    0.206     0.155 (0.007--3.662)
  Sample                      −2.179            0.142    0.127     0.113 (0.006--2.212)
  Time of sample collection   −2.133            0.171    0.182     0.118 (0.004--3.576)
  Test method                 0.283             1.888    0.848     1.328 (0.046--38.349)

*SE, standard error*.

![Deeks\' funnel plot for the assessment of potential publication bias in this meta-analysis.](fonc-09-00095-g0005){#F5}

Discussion {#s4}
==========

As is known, mammography as a screening method for breast cancer has the limitation of having low sensitivity. Hence, the circulating biomarkers, which can be easily collected and measured, have attracted the attention of more researchers. A correlation between increased levels of cfDNA and cancer has been widely studied ([@B29], [@B30]). Nowadays, it has been widely accepted that a solid tumor will obviously increase cfDNA concentrations ([@B31]). It was also demonstrated that the circulating cfDNA concentrations of breast cancer patients were significantly higher than healthy controls ([@B25]).

During the past decades, biomarkers of breast cancer have been widely discovered, such as CEA, CA15-3, HER2, and so on. CEA, which exists in the breast ductal secretions, showed a lower sensitivity of 58%, a lower AUC of 0.8750, and a lower DOR of 7.70 for breast cancer diagnosis ([@B32]). One study combined four biomarkers, including M-CSF, MMP-9, TIMP-1, and CA 15-3, drew a lower sensitivity, specificity, and AUC for breast cancer. The sensitivity, specificity, and AUC were 84%, 83%, and 0.9125, respectively ([@B33]).

In this study, we found a high diagnostic value of concentration of cfDNA, of which the sensitivity and specificity reached 87 and 87%, respectively. Additionally, AUC is considered as an indicator of good diagnostic performance when the value is \>0.90 ([@B34]). Therefore, the value of 0.93 in our study indicated that concentration of cfDNA had a good diagnostic accuracy for breast cancer. According to the above results, we can see that compared with other biomarkers of breast cancer, whether they are novel or classical, cfDNA may have better performance on detection of breast cancer.

We also conducted subgroup analyses. The results showed there were no obvious differences among the subgroup analyses for the sensitivity, specificity, and AUC. But the DORs varied from 15.80 to 79.11. When we only incorporated the studies using plasma samples, the highest sensitivity, specificity, and AUC of cfDNA on breast cancer detection were obtained, and they were also higher than pooled sensitivity, specificity, and AUC, respectively. These results indicated that plasma may be a better source for cfDNA in detection of breast cancer.

The original studies included in our analysis showed obvious differences in sensitivity and specificity. It is widely accepted that malignancy will increase the bloodstream concentration of cfDNA. However, in some abnormal condition, such as inflammation ([@B35]), arthritis ([@B36]), trauma ([@B37]), and even after exhaustive exercise ([@B38]), the concentration of cfDNA increases too. It reminds us that benign breast lesions and other illness should be firstly excluded when we use cfDNA to detect breast cancer. Also, the diagnostic efficiency of cfDNA on breast cancer detection can be much improved in combination with other known biomarkers (CA15-3, CEA, HER2, and so on) for breast cancer.

This study also contains several limitations. Firstly, as only 13 studies were included in this meta-analysis, compounded by the small number of included studies, it may be insufficient to yield a robust result. Secondly, heterogeneity existed between the selected studies, although it was impossible to determine all sources of heterogeneity. We did not include some covariates due to the unavailable data. These probable covariates included tumor stage, metastasis condition, tumor size, the risk of breast cancer, and so on. Thirdly, subgroup analyses on several covariates were unable to perform due to the various data, such as reference gene and cut-off value. Moreover, language bias might exist due to the references being restricted to English. Even so, to our knowledge, this study is the first to systematically evaluate the diagnostic value of the concentration of cfDNA in breast cancer in the whole population and various subgroups.

This meta-analysis suggests that the concentration of cfDNA has potential first diagnostic value for breast cancer due to the high sensitivity, specificity and AUC, and it may be a potential screening tool for breast cancer. In particular, plasma may be a better source of cfDNA in detection of breast cancer. Further large-scaled, well-designed studies are required to confirm our findings, and to provide a basis for future clinical practice. Moreover, the first diagnostic value of concentration of cfDNA for breast cancer could be validated by clinical trials.
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